
525 East 68th StreetStarr 900New York, NY 10065
Overview of Dr. Barbieri
Dr. Christopher Barbieri is a urologist based in New York, specializing in surgical oncology. He completed his medical education at Vanderbilt University, followed by residencies in surgery and urology at New York Presbyterian Hospital. Dr. Barbieri currently serves as an Attending Surgeon at New York-Presbyterian Hospital and Professor at Weill Cornell Medicine. His clinical expertise includes prostatectomy, robotic surgery, urologic oncology, genomics and genetics, and minimally invasive urologic surgery. He has authored multiple publications, with his research contributing to understanding prostate cancer. Dr. Barbieri has been recognized with several awards, including the MetLife Clinical Investigator Award and a Rising Star in Urology Research designation.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 2009 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2007 - 2009
Vanderbilt University School of MedicineClass of 2007
Certifications & Licensure
NY State Medical License 2009 - 2028
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
- MetLife Clinical Investigator Award Damon Runyon Cancer Research Foundation, 2016
Publications & Presentations
PubMed
- Trends in Prebiopsy MRI Utilization for Prostate Cancer Detection.Stephen Rhodes, Spyridon P Basourakos, Jim C Hu, Christopher E Barbieri, Angela Y Jia
JAMA Oncology. 2026-09-17 - Isoleucine and valine promote prostate cancer progression via propionyl-CoA-mediated cholesterol metabolism.Zhongchi Li, Shuchen Liu, Wenbing Jin, Leyi Xiao, Olivia Kester
Nature Metabolism. 2026-08-01 - Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial.Timothy D McClure, Shu Wang, Karla V Ballman, Marshall Diven, Joseph R Osborne
Radiology. 2026-07-01
Journal Articles
- Impact of Pelvic Radiation Therapy on Inflatable Penile Prosthesis Reoperation RatesChristopher E Barbieri, James A Kashanian, The Journal of Sexual Medicine
- Introduction to “Molecular Drivers of Prostate Cancer Development, Progression, and Resistance to Therapy”Christopher Barbieri, MD, Urologic Oncology
- Molecular Subtypes of Prostate CancerChristopher Barbieri, MD, Current Oncology Reports
Authored Content
- SPOP Mutated/ CHD1 Deleted Lethal Prostate Cancer and Abiraterone SensitivityMarch 2018
Press Mentions
Putting the Brakes on Prostate Cancer CellsDecember 13th, 2024
What You Need to Know About Prostate Cancer TreatmentsOctober 7th, 2024
Prostate Cancer’s Spread Modeled with CRISPR Barcoding TechnologySeptember 23rd, 2024
Grant Support
- The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancerWEILL MEDICAL COLL OF CORNELL UNIV2025–2030
- Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancerWEILL MEDICAL COLL OF CORNELL UNIV2025–2030
- Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancerWEILL MEDICAL COLL OF CORNELL UNIV2024–2029
- Collaborative genomic alterations and transcriptional control in prostate cancerWEILL MEDICAL COLL OF CORNELL UNIV2019–2025
- Coordinate Regulation of Oncogenic Signaling Pathways in SPOP Mutant Prostate CancerWEILL MEDICAL COLL OF CORNELL UNIV2018–2025
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: